SCHEMBL5823744

SCHEMBL5823744

CC(C)(C)[Si](C)(C)OCCn1cc(C=O)c2ccccc21

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.59
▸ TDP1 Q9NUW8 2/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ ALDH1A1 P00352 7/20 0.55
▸ SMN1; SMN2 Q16637 4/20 0.55
▸ HTT P42858 3/20 0.55
▸ NPC1 O15118 2/20 0.55
▸ MAPT P10636 2/20 0.55
▸ RAB9A P51151 2/20 0.55
▸ LMNA P02545 2/20 0.55
▸ HPGD P15428 1/20 0.55
▸ KMT2A Q03164 3/20 0.50
▸ IMPDH2 P12268 1/20 0.48
▸ MEN1 O00255 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30647201 1.00 POLB (0.59) POLBTDP1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL31370787 0.81 DUT (0.38) POLBTDP1L3MBTL1ALDH1A1MAPT
SCHEMBL1518274 0.80 POLB (0.71) POLBTDP1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL18616173 0.80 MCL1 (0.40) L3MBTL1MAPT
SCHEMBL13490857 0.78 POLB (0.66) POLBTDP1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL1779408 0.78 MAPT (0.58) POLBTDP1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL2263898 0.77 DUT (0.52) POLBTDP1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL2819961 0.77 ALDH1A1 (0.50) POLBTDP1ALDH1A1SMN1; SMN2HTT
SCHEMBL14522478 0.76 ICMT (0.58) —
SCHEMBL16146216 0.75 MCL1 (0.51) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108137542-B Pyridone dicarboxamides as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2023-10-27 — — CN disclosed
US-10927080-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2021-02-23 — — US disclosed
US-10927080-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2021-02-23 — — US disclosed
US-10428026-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-10-01 — — US disclosed
US-10428026-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-10-01 — — US disclosed
US-20180258044-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-09-13 — — US disclosed
WO-2017037116-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-03-09 — — WO disclosed
WO-2006105796-A1 NOVEL INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2006-10-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428026-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors BRD4, BRD3, BRDT POLB 756/4885TDP1 1320/4885L3MBTL1 4684/4885
US-20180258044-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRDT POLB 756/4885TDP1 1320/4885L3MBTL1 4684/4885
US-10927080-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors BRD4, BRD3, BRDT POLB 756/4885TDP1 1320/4885L3MBTL1 4684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback